The Personalis Mission
Our mission is to help cancer patients by enabling the next generation of personalized immuno-oncology therapeutics and diagnostics through rigorous innovation.
It Starts with Comprehensive Tumor Immunogenomics
Personalis is partnering with pharmaceutical companies to advance the development of more effective cancer immunotherapies by providing highly accurate and comprehensive tumor immunogenomics.
Our ACE ImmunoID Platform combines our augmented exome and transcriptome assays with advanced analytics to support our pharmaceutical partners at all stages of the drug development process; from discovery and translational research studies and clinical trials, to post-approval and commercialization.
The Universal Cancer Immunogenomics Platform
ImmunoID NeXT is the first platform to provide comprehensive analysis of both a tumor and its microenvironment from a single sample. It consolidates multiple oncology biomarker assays into one – maximizing the biological insights garnered from a single, precious tumor specimen. Traditionally, when samples are limited, researchers must make a difficult decision around which biomarkers to analyze. With ImmunoID NeXT, our partners no longer have to make this decision.
A Single Platform. A Single Sample. Multiple Biomarkers.
Personalis is offering pharmaceutical customers the opportunity to participate in an Early Access Program, beginning in January 2019.
Ready to streamline your precision oncology translational and clinical research programs?
Personalis Launches ImmunoID NeXT, the First Platform Providing Characterization of a Tumor and its Microenvironment from a Single Sample
Personalis Receives Approval from the New York State Dept. of Health for Use of its ACE ImmunoID™ Platform in Cancer Immunotherapeutic Clinical Trials
Personalis Launches ImmunogenomicsID™ for Multidimensional Immuno-Oncology Biomarker Analysis as the Latest Enhancement to the ACE ImmunoID™ Platform